Pinealon
Status
No approved product. No FDA-approved labeling exists. Not an FDA-approved medicine. Status in Russia and other countries was not verified for this entry.
What it is
A short peptide studied in animal models for brain cell protection.
What published research measured
A synthetic short peptide from the Khavinson programme directed at brain tissue, proposed to be neuroprotective and to influence cognition, and derived conceptually from work on pineal and brain tissue extracts. Rodent and cell studies from the originating group report protection against oxidative and hypoxic stress. This entry does not cite a registered clinical trial, independent replication of the central findings, or published human efficacy or pharmacokinetic data establishing that the peptide survives administration and reaches brain tissue in people. The proposed nuclear gene-regulation mechanism remains unconfirmed outside the programme.
Source
Khavinson programme preclinical publications
Sources
No linked primary source is on file for this entry yet.
Educational use only, never medical advice. No doses.